Drug Database
Back to search

Netherlands· NL-51e4cf2b980c

Xolremdi 100 mg harde capsule

A mavorixafor product containing mavorixafor, registered in Netherlands by Norgine B.V.. The same ATC class is registered in 7 of our 19 countries.

ATC L03AX24

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedXolremdi 100 mg harde capsuleATCL03AX24REGISTER NO.NL-51e4cf2b980cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mavorixaforAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mavorixafor is registered in 7 of 19 countries.

Countries holding a registration under ATC L03AX24 (mavorixafor), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search mavorixafor products by name

Mavorixafor · ATC L03AX24

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MAVORIXAFOR
Manufacturer
Norgine B.V.
Country
Netherlands (NL)
ATC code
L03AX24
ATC class
Mavorixafor
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/26/2017

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mavorixafor in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mavorixafor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Xolremdi
  • Liechtenstein · Xolremdi
  • Norway · Xolremdi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f7dd7173-19d2-41ad-946a-e6bec145d4ba
GET /v1/drugs/f7dd7173-19d2-41ad-946a-e6bec145d4ba?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/xolremdi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Mavorixafor",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134587",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 2-WATER (E 341)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "IJZEROXIDE ZWART (E 172)",
    "INDIGOKARMIJN (E 132)",
    "NATRIUMLAURILSULFAAT",
    "NATRIUMSTEARYLFUMARAAT",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "MAVORIXAFOR"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/04/27",
  "procedure_number": "EMEA/H/C/006496",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/26/2017",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about mavorixafor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console